Jack W. Singer
About
In The Last Decade
Jack W. Singer
462 papers receiving 24.5k citations
Hit Papers
Peers
Comparison fields: 5 of 176
- Hematology 15.8k
- Oncology 7.3k
- Molecular Biology 5.4k
- Immunology 5.4k
- Genetics 4.5k
Countries citing papers authored by Jack W. Singer
This map shows the geographic impact of Jack W. Singer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack W. Singer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack W. Singer more than expected).
Fields of papers citing papers by Jack W. Singer
This network shows the impact of papers produced by Jack W. Singer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack W. Singer. The network helps show where Jack W. Singer may publish in the future.
Co-authorship network of co-authors of Jack W. Singer
This figure shows the co-authorship network connecting the top 25 collaborators of Jack W. Singer. A scholar is included among the top collaborators of Jack W. Singer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack W. Singer. Jack W. Singer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 38 | |
| 2 | 9 | |
| 3 | 54 | |
| 4 | Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) | 4 |
| 5 | Performans Statusu 2 Olan ve İleri Evre Küçük Hücreli Dışı Akciğer Kanseri Olgularında Kombinasyona Karşı Tek Ajan Kemoterapisi İki Büyük Randomize Klinik Çalışma Çerçevesinde Prognostik Faktörler ve Tedavi Seçimi | 1 |
| 6 | Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis | 2 |
| 7 | 23 | |
| 8 | 41 | |
| 9 | Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. | 58 |
| 10 | 72 | |
| 11 | 34 | |
| 12 | 71 | |
| 13 | 0 | |
| 14 | 5 | |
| 15 | 45 | |
| 16 | Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation | 35 |
| 17 | 13 | |
| 18 | 40 | |
| 19 | Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. | 36 |
| 20 | One-hundred-ten patients with aplastic anemia (AA) treated by marrow transplantation in Seattle. | 37 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.